A Multi-National Study In Bladder Cancer Patients to Detect Recurrences After TURB (Trans-urethral Resection of the Bladder) Earlier With the Xpert Bladder Cancer Monitor Assay (ANTICIPATE X)

CompletedOBSERVATIONAL
Enrollment

852

Participants

Timeline

Start Date

June 6, 2018

Primary Completion Date

December 31, 2021

Study Completion Date

January 31, 2022

Conditions
Non-muscle-invasive Bladder Cancer
Interventions
DIAGNOSTIC_TEST

Xpert Bladder Cancer Monitor

The Xpert Bladder Cancer Monitor Assay is a qualitative in vitro diagnostic test designed to monitor for the recurrence of bladder cancer in patients previously diagnosed with bladder cancer. It should be used in conjunction with other clinical measures to assess disease recurrence. The test provides a fast and accurate result, is non-invasive and easy to perform.The test utilizes a voided urine specimen and measures the level of five target mRNAs (ABL1, CRH, IGF2, UPK1B, ANXA10) by means of real-time, reverse transcription-polymerase chain reaction (RT-PCR).

Trial Locations (13)

31100

CHU Toulouse / Institut Universitaire du Cancer Toulouse Oncopole, Toulouse

41345

Sahlgrenska University Hospital, Gothenburg

93053

University of Regensburg, Regensburg

Unknown

University Clinic for Urology and Andrology, Salzburg

Teaching Hospital Motol, Prague

Klinikum Braunschweig, Braunschweig

Humanitas University - Gradenigo Hospital of Turin, Turin

Instituto Valenciano de Oncologia, Valencia

Sunderland City Hospital, Sunderland

A-1090

Medical University of Vienna, Vienna

1105 AZ

Academic Medical Center, Amsterdam

08025

Fundacio Puigvert, Barcelona

GU2 7XX

Royal Surrey County Hospital, Guildford

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Axonal-Biostatem

INDUSTRY

collaborator

Stève Consultants

UNKNOWN

lead

Cepheid

INDUSTRY